D J Kuter

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
    David J Kuter
    Massachusetts General Hospital, Boston, MA 02114, USA
    Lancet 371:395-403. 2008
  2. ncbi request reprint Whatever happened to thrombopoietin?
    David J Kuter
    Transfusion 42:279-83. 2002
  3. ncbi request reprint Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres
    David J Kuter
    Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Br J Haematol 139:351-62. 2007
  4. doi request reprint Romiplostim
    David J Kuter
    Hematology Division, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Treat Res 157:267-88. 2011
  5. doi request reprint The biology of thrombopoietin and thrombopoietin receptor agonists
    David J Kuter
    Harvard Medical School, Boston, MA, USA
    Int J Hematol 98:10-23. 2013
  6. doi request reprint Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy
    David J Kuter
    Massachusetts General Hospital, Boston, MA 02114, USA
    Br J Haematol 161:411-23. 2013
  7. doi request reprint Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care
    David J Kuter
    Hematology Department, Massachusetts General Hospital, Boston, MA 02114, USA
    Am J Hematol 87:558-61. 2012
  8. ncbi request reprint Thrombopoietins and thrombopoiesis: a clinical perspective
    D J Kuter
    Hematology Oncology Unit, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    Vox Sang 74:75-85. 1998
  9. pmc New thrombopoietic growth factors
    David J Kuter
    Hematology Division, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    Blood 109:4607-16. 2007
  10. ncbi request reprint Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia
    David J Kuter
    Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Annu Rev Med 60:193-206. 2009

Detail Information

Publications39

  1. doi request reprint Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
    David J Kuter
    Massachusetts General Hospital, Boston, MA 02114, USA
    Lancet 371:395-403. 2008
    ..We assessed the long-term administration of romiplostim in splenectomised and non-splenectomised patients with ITP...
  2. ncbi request reprint Whatever happened to thrombopoietin?
    David J Kuter
    Transfusion 42:279-83. 2002
  3. ncbi request reprint Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres
    David J Kuter
    Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Br J Haematol 139:351-62. 2007
    ..This suggests new avenues for investigation into the pathogenesis of various disorders associated with increased bone marrow stromal fibres...
  4. doi request reprint Romiplostim
    David J Kuter
    Hematology Division, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Treat Res 157:267-88. 2011
    ..Future studies will assess the utility of romiplostim in CIT, hepatitis-C related thrombocytopenia, and MDS...
  5. doi request reprint The biology of thrombopoietin and thrombopoietin receptor agonists
    David J Kuter
    Harvard Medical School, Boston, MA, USA
    Int J Hematol 98:10-23. 2013
    ..Both have been highly effective in treating ITP and hepatitis C thrombocytopenia. Studies in a wide variety of other thrombocytopenic conditions are underway...
  6. doi request reprint Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy
    David J Kuter
    Massachusetts General Hospital, Boston, MA 02114, USA
    Br J Haematol 161:411-23. 2013
    ..In conclusion, this study demonstrated that romiplostim was safe and well-tolerated over 614 patient-years of exposure in ITP patients, and that efficacy was maintained with stable dosing for up to 5 years of continuous treatment...
  7. doi request reprint Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care
    David J Kuter
    Hematology Department, Massachusetts General Hospital, Boston, MA 02114, USA
    Am J Hematol 87:558-61. 2012
    ..Overall, treatment of ITP was associated with improvement in HRQOL. Patients receiving romiplostim had greater HRQOL improvements than those receiving SOC, but the magnitude ofthe difference is of uncertain clinical benefit...
  8. ncbi request reprint Thrombopoietins and thrombopoiesis: a clinical perspective
    D J Kuter
    Hematology Oncology Unit, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    Vox Sang 74:75-85. 1998
    ..Their impact on platelet usage is still unclear but may be less than initially estimated...
  9. pmc New thrombopoietic growth factors
    David J Kuter
    Hematology Division, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    Blood 109:4607-16. 2007
    ..One or more second-generation thrombopoietic growth factors should soon be clinically available for treating thrombocytopenic disorders...
  10. ncbi request reprint Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia
    David J Kuter
    Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Annu Rev Med 60:193-206. 2009
    ..Ongoing studies should establish the incidence of these complications and determine the efficacy of these new agents in a variety of other thrombocytopenic conditions...
  11. doi request reprint Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim
    David J Kuter
    Massachusetts General Hospital, Boston, MA 02114, USA
    Blood 114:3748-56. 2009
    ..These studies were registered at www.clinicaltrials.gov as #NCT00102323, #NCT00102336, #NCT00861224, and #NCT00116688...
  12. doi request reprint New thrombopoietic growth factors
    David J Kuter
    Hematology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Clin Lymphoma Myeloma 9:S347-56. 2009
    ..Studies are under way to assess the efficacy of these drugs in the treatment of other thrombocytopenic disorders associated with chemotherapy, myelodysplasia, and chronic hepatitis...
  13. pmc Biology and chemistry of thrombopoietic agents
    David J Kuter
    Hematology Division, Massachusetts General Hospital, Boston, MA 02114, USA
    Semin Hematol 47:243-8. 2010
    ..Both have been highly effective in increasing the platelet count in patients with ITP and are currently being studied in the treatment of other thrombocytopenic conditions (myelodysplastic syndrome, chemotherapy, liver disease)...
  14. ncbi request reprint Thrombotic complications of central venous catheters in cancer patients
    David J Kuter
    Hematology Oncology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Oncologist 9:207-16. 2004
    ..Newer anticoagulant treatments, such as pentasaccharide and direct thrombin inhibitors, need to be explored to address this major medical problem...
  15. ncbi request reprint Apoptosis in platelets during ex vivo storage
    David J Kuter
    Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Vox Sang 83:311-3. 2002
  16. ncbi request reprint Recombinant human thrombopoietin: basic biology and evaluation of clinical studies
    David J Kuter
    Hematology Oncology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Blood 100:3457-69. 2002
    ..Ongoing and future studies will help define the clinical role of recombinant TPO and TPO mimetics in the treatment of chemotherapy- and nonchemotherapy-induced thrombocytopenia...
  17. ncbi request reprint Thrombopoietin therapy increases platelet yields in healthy platelet donors
    D J Kuter
    Hematology Oncology Unit, Massachusetts General Hospital, Boston 02114, USA
    Blood 98:1339-45. 2001
    ..Thrombopoietin therapy can increase platelet counts in healthy donors to provide a median 3-fold more apheresis platelets compared with untreated donors...
  18. doi request reprint What is the potential for thrombopoietic agents in acute leukemia?
    David J Kuter
    Harvard Medical School, Massachusetts General Hospital, Yawkey, Boston, MA 02114, USA
    Best Pract Res Clin Haematol 24:553-8. 2011
    ....
  19. ncbi request reprint Thrombocytopenia caused by the development of antibodies to thrombopoietin
    J Li
    Hematology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Blood 98:3241-8. 2001
    ..These data demonstrate a new mechanism for thrombocytopenia in which antibody develops to TPO; because endogenous TPO is produced constitutively, thrombocytopenia ensues...
  20. ncbi request reprint The effect of unfractionated vs. low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients
    J R Brown
    Department of Medicine, Massachusetts General Hospital, Boston 02114, USA
    Thromb Haemost 85:979-85. 2001
    ..Given the increasing number of studies establishing the clinical efficacy of low molecular weight heparins as antithrombotic agents, these results suggest that TFPI may not be a major contributor to the antithrombotic effect of heparin...
  21. ncbi request reprint The end is just the beginning: megakaryocyte apoptosis and platelet release
    J Li
    Hematology Oncology Unit, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    Int J Hematol 74:365-74. 2001
    ..This review summarizes recent research progress on megakaryocyte apoptosis and platelet release...
  22. doi request reprint Romiplostim or standard of care in patients with immune thrombocytopenia
    David J Kuter
    Massachusetts General Hospital, Boston, MA 02114, USA
    N Engl J Med 363:1889-99. 2010
    ..Romiplostim, a thrombopoietin mimetic, increases platelet counts in patients with immune thrombocytopenia, with few adverse effects...
  23. pmc Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy
    Paul G Richardson
    Dana Farber Cancer Institute, 44 Binney St, Dana 1B02, Boston, MA 02115, USA
    J Clin Oncol 27:3518-25. 2009
    ..Baseline myeloma-associated neuropathy seems more common than previously reported, and bortezomib-associated neuropathy, although a common toxicity, is reversible in most patients...
  24. ncbi request reprint Apoptotic markers are increased in platelets stored at 37 degrees C
    A M Bertino
    Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Transfusion 43:857-66. 2003
    ..Because PLTs contain an intact apoptotic mechanism, we sought to determine whether PLTs undergo apoptosis during storage and whether storage at 37 degrees C accelerated this process...
  25. ncbi request reprint The physiological response of thrombopoietin (c-Mpl ligand) to thrombocytopenia in the rat
    C Yang
    Hematology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Br J Haematol 105:478-85. 1999
    ..These results serve as a proof that the circulating level of TPO is determined not by alterations in TPO transcription or translation but by the ability of the platelet mass to bind and remove TPO from the circulation...
  26. ncbi request reprint Catheter-related thrombosis in cancer patients: pathophysiology, diagnosis, and management
    Rachel P Rosovsky
    Hematology Oncology Unit, Massachusetts General Hospital, Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
    Hematol Oncol Clin North Am 19:183-202, vii. 2005
    ..Efforts to use prophylactic heparin or warfarin to reduce catheter-related DVT have not been rewarding...
  27. ncbi request reprint Cancer, coagulation, and anticoagulation
    A Letai
    Hematology Oncology Department, Massachusetts General Hospital Cancer Center, Boston, USA
    Oncologist 4:443-9. 1999
    ..Whether anticoagulants might also improve cancer survival rates independent of their effect on thromboembolism deserves further investigation...
  28. pmc Thrombopoietin and platelet production in chronic immune thrombocytopenia
    David J Kuter
    Harvard Medical School, Boston, MA, USA
    Hematol Oncol Clin North Am 23:1193-211. 2009
    ..This article reviews the biology of TPO, the regulation of its circulating level in ITP, the platelet kinetic data supporting inappropriate platelet production in ITP, and the TPO mimetic agents available to treat ITP...
  29. ncbi request reprint Effect of thrombopoietin alone and a combination of cytochalasin B and ethylene glycol bis(beta-aminoethyl ether) N,N'-tetraacetic acid-AM on the survival and function of autologous baboon platelets stored at 4 degrees C for as long as 5 days
    C Robert Valeri
    Naval Blood Research Laboratory, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Transfusion 44:865-70. 2004
    ....
  30. ncbi request reprint Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use
    Stanley A Nasraway
    Division of Surgical Critical Care, Department of Surgery, Tufts New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
    Clin Infect Dis 37:1609-16. 2003
    ..Clinically significant thrombocytopenia was uncommon in our analysis, and linezolid was not associated with a greater risk of thrombocytopenia in seriously ill patients than was vancomycin...
  31. doi request reprint ADAMTS13 binds to CD36: a potential mechanism for platelet and endothelial localization of ADAMTS13
    Amanda K Davis
    Department of Pathology, Massachusetts General Hospital, Boston, USA
    Transfusion 49:206-13. 2009
    ..CD36, a transmembrane protein present on endothelial cells and platelets (PLTs), binds to thrombospondin via three thrombospondin type 1 repeats. ADAMTS13 contains eight thrombospondin type 1 repeats...
  32. ncbi request reprint Dalteparin-induced skin necrosis in a patient with metastatic lung adenocarcinoma
    Allan Moore
    Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Am J Clin Oncol 30:329-31. 2007
  33. ncbi request reprint Successful recovery after an overdose of argatroban
    Andrew J Yee
    Hematology Oncology Unit, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114 2621, USA
    Ann Pharmacother 40:336-9. 2006
    ..To report the case of a critically ill man with heparin-induced thrombocytopenia (HIT) who received a 125 mg overdose of the direct thrombin inhibitor argatroban...
  34. ncbi request reprint Effects of biochemically confirmed smoking cessation on white blood cell count
    Gregory A Abel
    Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Mayo Clin Proc 80:1022-8. 2005
    ..To determine the relationship between white blood cell (WBC) Indices and several baseline variables In a large cohort of healthy smokers and to assess whether these changed after biochemically confirmed smoking cessation...
  35. ncbi request reprint Successful treatment of pure red cell aplasia with autologous stem cell transplantation
    Jae H Park
    MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Am J Hematol 82:812-4. 2007
    ..The patient remains in complete remission and on no other therapy for 36 months following the autologous HSCT...
  36. ncbi request reprint The promise of thrombopoietins in the treatment of ITP
    David J Kuter
    Clin Adv Hematol Oncol 3:464-6. 2005
  37. ncbi request reprint Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project
    Charles L Bennett
    VA Midwest Center for Health Services and Policy Research, the Jesse Brown VA Medical Center, Chicago, IL, USA
    Br J Haematol 135:642-50. 2006
    ..While a causal relationship with haematological malignancies cannot be demonstrated, long-term follow-up among healthy individuals who receive haematopoietic growth factors is needed...
  38. ncbi request reprint AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP
    James B Bussel
    New York Presbyterian Hospital, New York, USA
    N Engl J Med 355:1672-81. 2006
    ..Most current treatments for chronic immune thrombocytopenic purpura (ITP) act by decreasing platelet destruction. In a phase 1-2 study, we administered a thrombopoiesis-stimulating protein, AMG 531, to patients with ITP...
  39. pmc Hematologic effects of linezolid: summary of clinical experience
    Stanton L Gerson
    Division of Hematology Oncology and Ireland Cancer Center, Case Western Reserve University, University Hospitals of Cleveland, 10900 Euclid Avenue, Cleveland, OH 44106 4937, USA
    Antimicrob Agents Chemother 46:2723-6. 2002
    ..Hematologic abnormalities were consistent with mild, reversible, duration-dependent myelosuppression. Appropriate monitoring is warranted with linezolid use...